+49 711 500 989 80
deen

Targeted drug achieves 43% response rate in KRAS-mutated lung cancer



Targeted drug achieves 43% response rate in KRAS-mutated lung cancer

Nearly 43% of patients with non-small cell lung cancer (NSCLC) whose lung cancers harbored a specific KRAS mutation responded to the experimental drug adagrasib, and the targeted agent also showed activity against lesions in the brain that metastasized from the lung tumors, according to results of a new study.

Materials provided by Dana-Farber Cancer Institute. Note: Content may be edited for style and length.




Source link aaaaa

Related posts

1st July 2022

New method boosts the study of regulation of gene activity

Read more
1st July 2022

Researchers discover new leukemia-killing compounds

Read more
30th June 2022

Research reveals structure of a human endogenous reverse transcriptase

Read more